Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer

Challapalli, Amarnath; Barwick, Tara; Tomasi, Giampaolo; Doherty, M. O; Contractor, Kaiyumars; Stewart, Simon; Al‐Nahhas, Adil; Behan, Kevin; Coombes, R. Charles; Aboagye, Eric O.; Mangar, Stephen

doi:10.1097/mnm.0000000000000014

Cited by 24 publications

(21 citation statements)

References 26 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Single case reports or small case series have been reported that suggest 18F-NaF and 11C-choline may be useful in the assessment response to Ra-223 dichloride therapy [49, 50]. Similar preliminary results have been reported for effects of neodjuvant androgen deprivation and radical prostate radiotherapy with concurrent androgen deprivation therapy on uptake level of 11C-choline in tumors [51, 52]. There is currently no experience with other PET radiotracers in the clinical setting of treatment response assessment in patients with prostate cancer.…”

Section: Treatment Response Evaluation and Prognosticationmentioning

confidence: 68%

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer

Jadvar

2016

Abdom Radiol

View full text Add to dashboard Cite

Prostate cancer is a prevalent public health problem worldwide. While imaging has played a major role in this disease, there still remain many challenges and opportunities. Positron emission tomography with various physiologically based radiotracers is fundamentally suited to interrogate this biologically and clinically heterogeneous disease along the course of its natural history. In this article, I review briefly the published evidence for the use of positron emission tomography with 18F-fluorodeoxyglucose, 11C-acetate, and 18F- or 11C-choline in the imaging evaluation of prostate cancer. Although the focus of the article will be on these radiotracers given the accumulated experience with them, but I will also comment on the outlook for the use of other emerging PET radiotracers such as those targeted to the prostate-specific membrane antigen and the amino acid metabolism pathway. It is anticipated that PET will play major role in the evaluation of prostate cancer in the current evidence-based medicine environment. There will also be exciting novel prospects for the use of therapeutic-diagnostic (theransotic) pairs in the management of patients with prostate cancer.

show abstract

Section: Treatment Response Evaluation and Prognosticationmentioning

confidence: 68%

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer

Jadvar

2016

Abdom Radiol

View full text Add to dashboard Cite

show abstract

“…Gebhart et al reported that, in 86 HER2-positive breast cancer patients, only 77 patients had an evaluable baseline signaling using (18)F-FDG PET/CT scans [43]. FDG-PET/CT cannot reliably detect tumors <0.5 cm in size and, thus, cannot reliably detect emerging metastasis in tumors that acquire resistance to targeted drugs and undergoing metastasis [44, 45]. Timely monitoring of the onset of disease recurrence or the emergence of secondary resistance to targeted drugs continues to be a major challenge.…”

Section: Discussionmentioning

confidence: 99%

Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts

et al. 2015

View full text Add to dashboard Cite

BackgroundAlthough targeted therapies have improved the clinical outcomes of cancer treatment, tumors resistance to targeted drug are often detected too late and cause mortality. CSE1L is secreted from tumor and its phosphorylation is regulated by ERK1/2. ERK1/2 is located downstream of various growth factor receptors and kinases, the targets of most targeted drugs. Serum phospho-CSE1L may be a marker for monitoring the efficacy of targeted therapy.MethodsWe used mice tumor xenograft model to study the assay of serum phosphorylated CSE1L for early detecting the efficacy of targeted drugs. The phosphorylation status of CSE1L in vemurafenib and sorafenib treated tumor cells were assayed by immunoblotting with antibody against phosphorylated CSE1L.ResultsRas activation increased phospho-CSE1L expression in B16F10 melanoma cells. Vemurafenib and sorafenib treatment did not significantly reduce the total CSE1L levels; however, they inhibited ERK1/2 and CSE1L phosphorylation in A375 melanoma cells and HT-29 colorectal cancer cells. In the melanoma xenograft model, serum phospho-CSE1L level declined 5 days after vemurafenib/sunitinib treatment and 3 days after sorafenib/lapatinib treatment in the HT-29 colon cancer xenograft model. Vemurafenib/sunitinib and sorafenib/lapatinib treatments resulted in tumor regression.ConclusionsOur results indicated that serum phospho-CSE1L is useful for early detecting the efficacy of targeted therapy in initial treatment and for monitoring emerging secondary drug resistance to facilitate timely therapeutic decision making.

show abstract

“…One hundred paraffin-embedded malignant prostate tumour cores (including 20 cores from patients whose primary and IHC data have been previously published,20 and 10 cores from patients recruited to the choline response study19) and 25 normal prostate cores were analysed. The 70 malignant cores were obtained from consecutive patients who had neoadjuvant androgen deprivation and radical radiotherapy for their prostate cancer.…”

Section: Methodsmentioning

confidence: 99%

Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer

Cited by 24 publications

References 26 publications

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer

Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts

Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer

Contact Info

Product

Resources

About